NICE Rejects Roche’s Avastin For Ovarian Cancer Due To Excessive Cost
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche’s extremely high price for Avastin results in yet another knock-back by Britain’s NICE, this time for advanced ovarian cancer.